How should anti‑M antibodies be managed in pregnancy, including monitoring of antibody titers and fetal surveillance?

Management of Anti-M Antibodies in Pregnancy

Anti-M antibodies in pregnancy require minimal surveillance in most cases, as severe hemolytic disease of the fetus and newborn (HDFN) is exceedingly rare with this antibody, and routine intensive monitoring is not warranted unless specific high-risk features are present.

Initial Assessment and Risk Stratification

When anti-M antibodies are detected during routine prenatal screening, the first critical step is determining the antibody characteristics and titer:

• Check if the antibody is IgG class and reactive at 37°C – only IgG antibodies that react at body temperature can cross the placenta and potentially cause HDFN 1, 2
• Obtain initial antibody titer – most anti-M antibodies remain at titers ≤1:4 throughout pregnancy 3, 4
• Determine paternal M antigen status – if the father is M antigen negative (NN genotype), the fetus cannot be affected and no further monitoring is needed 2

Monitoring Strategy Based on Risk Profile

Low-Risk Pregnancies (Majority of Cases)

For pregnancies with anti-M titer ≤1:4, no concerning obstetric history, and IgM or non-reactive antibodies at 37°C:

• Repeat antibody screen at 28 weeks gestation only to detect emergence of other clinically significant antibodies 4
• No serial titers, amniocentesis, or MCA-PSV Doppler surveillance required 3, 4
• Test infant's M antigen status and perform direct antiglobulin test (DAT) at delivery

This conservative approach is justified by extensive retrospective data: in a 15-year review of 195 pregnancies with anti-M antibodies, there were zero cases of HDFN despite 73.6% of infants being M antigen positive 3. Similarly, a 26-year review of 115 pregnancies found no cases of mild or severe HDFN 4.

High-Risk Pregnancies (Rare)

Initiate enhanced surveillance if ANY of the following are present:

• Initial titer ≥1:8 or rising titers (>2-fold increase)
• IgG antibody reactive at 37°C
• Prior pregnancy complicated by fetal anemia, hydrops, or intrauterine death
• History suggesting hemolytic disease in previous pregnancies

For high-risk cases, follow general red cell alloimmunization guidelines 5:

• Determine fetal M antigen status using cell-free fetal DNA if available
• If fetus is M antigen positive or status unknown:
  • Initiate weekly MCA-PSV Doppler measurements starting at 16 weeks gestation once critical titer threshold is reached 5
  • Critical titer for most antibodies is ≥16, but use clinical judgment for anti-M given its typically benign nature
  • MCA-PSV ≥1.5 multiples of the median (MoM) predicts moderate-severe fetal anemia with 100% sensitivity 6

Critical Pitfalls and Caveats

The direct antiglobulin test (DAT) may be negative even when hemolysis is occurring in anti-M mediated disease 7, 2. This is a unique feature of anti-M antibodies that can lead to missed diagnosis. Therefore:

• Always test the infant's M antigen status at delivery
• Monitor for clinical signs of anemia and hyperbilirubinemia even with negative DAT
• Consider phototherapy threshold adjustments for M antigen-positive infants

Rare but severe cases exist: While extremely uncommon, severe fetal anemia, hydrops fetalis, and intrauterine death have been documented with anti-M 7. One case series reported three pregnancies in one family with severe outcomes, including one intrauterine death at 20 weeks and hydrops requiring intrauterine transfusion 7. This underscores the importance of not completely dismissing anti-M, particularly with concerning obstetric history.

Temperature considerations: For patients requiring surgery where core body temperature may drop, even IgM anti-M antibodies can become clinically significant 8. Ensure M antigen-negative blood is available for surgical patients.

Delivery and Neonatal Management

• Timing of delivery: No specific modifications needed for uncomplicated anti-M pregnancies; follow standard obstetric indications
• Neonatal testing: Obtain infant's M antigen status, DAT, complete blood count, and bilirubin levels
• Phototherapy: Nine infants required phototherapy in one large series, mostly preterm infants 4
• Transfusion: If neonatal transfusion is required, use M antigen-negative blood

Key Distinction from Other Antibodies

Unlike anti-D, anti-Kell, or anti-c antibodies where the 2025 JAMA guidelines recommend aggressive surveillance with specific critical titer thresholds (≥16 for most antibodies, ≥4 for anti-Kell) 5, anti-M does not follow these same protocols unless high-risk features are present. The evidence overwhelmingly demonstrates that anti-M behaves differently, with the vast majority of cases being clinically insignificant 3, 4.